There are multiple examples of oncogenic mutations that predict benefit from FDA-approved targeted therapies (CML/imatinib, melanoma/BRAFi, lung/EGFR and ALK inhibitors, breast/HER2 inhibitors), and other mutations that predict resistance (RAS mutations and EGFR inhibitors). Here, ALK is linked to chronic myelogenous leukemia, BCR-ABL1 positive.